Annual report pursuant to Section 13 and 15(d)

Consolidated Balance Sheets

v3.20.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Current assets:    
Cash and cash equivalents $ 85,451 $ 87,721
Marketable securities, current 39,633 10,234
Prepaid expenses 2,318 2,244
Grant revenue receivable 7,100 4,329
Accounts receivable from related party 408 240
In-process research and development - held for sale 4,500 0
Other current assets 489 95
Total current assets 139,899 104,863
Marketable securities, non-current 1,510 0
Operating lease right-of-use assets, non-current 9,959 0
Property and equipment, net 18,158 6,851
In-process research and development 0 26,623
Other assets 4,676 1,821
Total assets 174,202 140,158
Current liabilities:    
Accounts payable 1,465 780
Accrued liabilities 14,544 5,357
Deferred revenue, current 17,291 26,231
Other current liabilities 2,501 141
Total current liabilities 35,801 32,509
Deferred revenue, long-term 19,385 2,670
Long-term debt, net 2,940 3,254
Operating lease liabilities, non-current 11,682 0
Other liabilities 1,366 819
Total liabilities 71,174 39,252
Commitments and contingencies (Note 10) 0 0
Stockholders’ equity:    
Preferred stock, $0.001 par value: Authorized: 2,000,000 at December 31, 2019 and 2018; Issued and outstanding: 250 and zero shares at December 31, 2019 and 2018, respectively. 0 0
Common stock, $0.001 par value: Authorized: 150,000,000 shares at December 31, 2019 and 2018; Issued and outstanding: 45,589,157 and 36,736,012 shares at December 31, 2019 and 2018, respectively. 46 37
Additional paid-in capital 267,089 195,573
Accumulated other comprehensive loss 18 0
Accumulated deficit (164,125) (94,704)
Total stockholders’ equity 103,028 100,906
Total liabilities and stockholders’ equity $ 174,202 $ 140,158